Venetoclax Plus LDAC May Benefit Patients with AML Ineligible for Intensive Chemotherapy

A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news